5.59
+0.13
(2.38%)
May 24 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 5.44 - 5.71 |
| 52 week | 3.85 - 5.71 |
| Open | 5.44 |
| Vol / Avg. | 170,357.00/206,038.00 |
| Mkt cap | 187.93M |
| P/E | - |
| Div/yield | - |
| EPS | -0.52 |
| Shares | 33.62M |
| Beta | 3.03 |
| Inst. own | 83% |
Events
Aug 5, 2013
Q2 2013 Targacept, Inc. Earnings Release
Jun 6, 2013
Targacept, Inc. at Jefferies Global Healthcare Conference
- 1:00PM EDT -
May 29, 2013
Targacept, Inc. at Deutsche Bank dbAccess Health Care Conference
- 11:20AM EDT -
May 7, 2013
Q1 2013 Targacept, Inc. Earnings Conference Call -
Apr 30, 2013
Targacept, Inc. at Needham Healthcare Conference -
Apr 29, 2013
Q1 2013 Targacept, Inc. Earnings Release
Mar 5, 2013
Targacept, Inc. at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -228.11% | -12.09% |
| Operating margin | -233.99% | -14.06% |
| EBITD margin | - | -3.82% |
| Return on average assets | -17.57% | -3.13% |
| Return on average equity | -18.74% | -4.00% |
| Employees | 40 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 1510, 100 North Main Street
WINSTON-SALEM, NC 27101
United States - Map
+1-336-4802100 (Phone)
+1-336-4802107 (Fax)
WINSTON-SALEM, NC 27101
United States - Map
+1-336-4802100 (Phone)
+1-336-4802107 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple clinical-stage product candidates and preclinical programs in areas. The Company's drug discovery activities utilize computer-based molecular design methodologies and biological and chemical data for a library of diverse compounds developed and collected. The Company refers to these technologies collectively as Pentad. Its clinical-stage product candidates include TC-5214, TC-5619, TC-6987, AZD3480 (TC-1734), AZD1446 (TC-6683), TC-6499 and TC-6987.
Officers and directors
| Mark B. Skaletsky Ph.D. | Independent Chairman of the Board | |
| Stephen A. Hill M.D. | President, Chief Executive Officer, Director | |
| Alan A Musso C.P.A CMA | CFO, Senior Vice President - Finance and Administration, Treasurer, Assistant Secretary | |
| Peter A Zorn Esq. | Senior Vice President - Legal Affairs, General Counsel, Secretary | |
| Merouane Bencherif M.D.,Ph.D. | Senior Vice President - Preclinical Research | |
| Mauri K Hodges C.P.A. | Vice President - Finance and Corporate Systems, Controller | |
| Karen A Hicks | Vice President - Human Resources | |
| M. James Barrett Ph.D. | Independent Director | |
| Charles A. Blixt Esq. | Independent Director | |
| Julia R. Brown | Independent Director |